Core Insights - Rhenium (Re) Obisbemeda shows promising safety and efficacy for glioblastoma patients, with a median overall survival of 17 months for those receiving doses greater than 100 Gy, compared to 8 months with standard care [1][7] - The publication of Phase 1 trial results in a high-impact journal validates the clinical program and supports the ongoing ReSPECT-GBM Phase 2 trial [2] Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system cancers, particularly recurrent glioblastoma and leptomeningeal metastases [9] - The company utilizes advanced platform technologies to enhance patient outcomes through targeted drug delivery and image-guided local beta radiation [9] Clinical Trial Details - The ReSPECT-GBM trial is currently enrolling patients and aims to provide a much-needed treatment option for recurrent glioblastoma, which has limited existing therapies [2][3] - Rhenium (Re) Obisbemeda is being evaluated in clinical trials, including ReSPECT-GBM and ReSPECT-LM, with significant funding support from the National Cancer Institute and a $17.6 million grant from the Cancer Prevention & Research Institute of Texas [5] Disease Context - Glioblastoma affects approximately 15,000 patients annually in the U.S. and is characterized by a poor prognosis, with an average life expectancy of less than 24 months [4] - Current treatments for recurrent glioblastoma offer marginal survival benefits and are associated with significant side effects, highlighting the need for more effective therapies [4] Treatment Mechanism - Rhenium (Re) Obisbemeda is a novel injectable radiotherapy designed to deliver high doses of targeted radiation directly to CNS tumors, potentially improving outcomes compared to existing therapies [5] - The treatment utilizes Rhenium-186, which has a short half-life and is effective for both destroying cancerous tissue and real-time imaging [5]

Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PLUS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 33-0827593 (Primary Standard Industrial Classification Code Number) Table of Contents As filed with the Securities and Exchange Commission on June 24, 2024 Registration No. 333-280061 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (I.R.S. Employer ...

Table of Contents As filed with the Securities and Exchange Commission on March 8, 2024 Registration No. 333-275712 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO Form S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 PLUS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 33-0827593 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer ...

Table of Contents As filed with the Securities and Exchange Commission November 22, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of Registrant as specified in its charter) Delaware 2834 33-0827593 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial (I.R.S. Employer Identification Number) 4200 Marathon Blvd., Suite 200 Austin, TX 78756 (737)-255-7194 (Address, including zip code, and telephone number, in ...

Table of Contents As filed with the Securities and Exchange Commission November 14, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 PLUS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 33-0827593 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) ...